Trial · NCT03559192
Adverse events15
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 15 of 15
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Diarrhoea | Gastrointestinal disorders | Lead in Period: Placebo | 6 | 169 | |
| other | Diarrhoea | Gastrointestinal disorders | Double-blind Treatment + Withdrawal Period: Placebo | 2 | 84 | |
| other | Diarrhoea | Gastrointestinal disorders | Double-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg) | 7 | 85 | |
| other | Nasopharyngitis | Infections and infestations | Lead in Period: Placebo | 6 | 169 | |
| other | Nasopharyngitis | Infections and infestations | Double-blind Treatment + Withdrawal Period: Placebo | 3 | 84 | |
| other | Nasopharyngitis | Infections and infestations | Double-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg) | 6 | 85 | |
| other | Headache | Nervous system disorders | Lead in Period: Placebo | 11 | 169 | |
| other | Headache | Nervous system disorders | Double-blind Treatment + Withdrawal Period: Placebo | 7 | 84 | |
| other | Headache | Nervous system disorders | Double-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg) | 10 | 85 | |
| other | Pruritus | Skin and subcutaneous tissue disorders | Lead in Period: Placebo | 1 | 169 | |
| other | Pruritus | Skin and subcutaneous tissue disorders | Double-blind Treatment + Withdrawal Period: Placebo | 0 | 84 | |
| other | Pruritus | Skin and subcutaneous tissue disorders | Double-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg) | 5 | 85 | |
| serious | Cholecystitis Acute | Hepatobiliary disorders | Lead in Period: Placebo | 0 | 169 | 0 |
| serious | Cholecystitis Acute | Hepatobiliary disorders | Double-blind Treatment + Withdrawal Period: Placebo | 1 | 84 | 1 |
| serious | Cholecystitis Acute | Hepatobiliary disorders | Double-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg) | 0 | 85 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03559192/events